Abstract-Plasminogen activator inhibitor type-1 (PAI-1) is a major physiological inhibitor of fibrinolysis, with its plasma levels correlating with the risk for myocardial infarction and venous thrombosis. The regulation of PAI-1 transcription by endothelial cells (ECs), a major source of PAI-1, remains incompletely understood. Adipocytes also produce PAI-1, suggesting possible common regulatory pathways between adipocytes and ECs. Peroxisomal proliferator-activated receptor-␥ (PPAR)␥ is a ligand-activated transcription factor that regulates gene expression in response to various mediators such as 15-deoxy-⌬12,14 -prostaglandin J 2 (15d-PGJ 2 ) and oxidized linoleic acid (9-and 13-HODE). The present study tested the hypotheses that human ECs express PPAR␥ and that this transcriptional activator regulates PAI-1 expression in this cell type. We found that human ECs contain both PPAR␥ mRNA and protein. Immunohistochemistry of human carotid arteries also revealed the presence of PPAR␥ in ECs. Bovine ECs transfected with a PPAR response element (PPRE)-luciferase construct responded to stimulation by the PPAR␥ agonist 15d-PGJ 2 in a concentration-dependent manner, suggesting a functional PPAR␥ in ECs. Treatment of human ECs with 15d-PGJ 2 , 9(S)-HODE, or 13(S)-HODE augmented PAI-1 mRNA and protein expression, whereas multiple PPAR␣ activators did not change PAI-1 levels. Introduction of increasing amounts of a PPAR␥ expression construct in human fibroblasts enhanced PAI-1 secretion from these cells in proportion to the amount of transfected DNA. Thus, ECs express functionally active PPAR␥ that regulates PAI-1 expression in ECs. Key Words: atherosclerosis Ⅲ endothelium Ⅲ peroxisomal proliferator-activated receptor Ⅲ plasminogen activator inhibitor-1 Ⅲ 15-deoxy-⌬12,14 -prostaglandin J 2
ndothelial cells (ECs) are an important source of plasminogen activator inhibitor type-1 (PAI-1) plasma activity. 1 PAI-1, a member of the serine protease inhibitor (serpin) family, is the major physiological inhibitor of tissue plasminogen activator and urokinase and thus, limits fibrinolysis. 2 Considerable evidence links PAI-1 to myocardial infarction and deep venous thrombosis [3] [4] [5] ; endothelial production of PAI-1 likely influences these events. As such, the regulation of PAI-1 expression in ECs has received focused attention. 6 -8 Cytokines such as transforming growth factor-␤ and tumor necrosis factor-␣ increase PAI-1 expression. 9, 10 Circulating lipids, 11 some lipid-lowering therapies, 12 and the clinical condition of obesity itself 2 all affect PAI-1 expression. This response to lipids, as well as the evidence that adipocytes themselves can express PAI-1, 13 raises the possibility that transcriptional mediators important in adipogenesis and adipocyte signaling may play similar roles in ECs.
Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor superfamily, are ligand-activated transcription factors that play an important role in lipid metabolism. 14 -16 One of these PPARs, PPAR␥, has been implicated in the transcriptional regulation of several genes involved in lipid metabolism and appears to promote the differentiation of cells toward a more adipocyte-like phenotype. [17] [18] [19] Both synthetic and natural ligands for PPAR␥ have been described. Among the synthetic ligands, thiazolidinediones, a group of compounds that includes troglitazone, increase insulin sensitivity. 20 Naturallyoccurring PPAR␥ ligands include fatty acids, eicosanoid derivatives, 21 and 15-deoxy-⌬12, 14 -prostaglandin J 2 (15d-PGJ 2 ). 19 Recent work has established that 9-hydroxy-(S)-10,12-octadecadienoic acid [9(S)-HODE] and 13(S)-HODE, known components of oxidized LDL, are PPAR␥ activators, with concomitant evidence invoking PPAR␥ signaling in monocytes and macrophages. 22, 23 Clinical observations suggest that obese patients have elevated adipose tissue PPAR␥ levels compared with those in lean controls. 24 Once activated, PPAR␥ binds to the PPAR response elements (PPRE) in the promotor region of target genes. [25] [26] [27] Although PPAR␥ has been extensively studied in adipocytes, monocytes/macrophages, and vascular smooth muscle cells, 22,23,28 -30a essentially nothing is known about PPAR␥ in EC biology and gene expression.
The present study investigated whether PPAR␥ was expressed and active in human ECs, and if so, whether PPAR␥ might regulate PAI-1 expression in this cell type, abundant in adipose tissue. In addition to focusing attention on the possible role of PPAR␥ signaling in ECs, such findings offer a novel molecular link between the clinical associations between obesity, coagulation status, and vascular events.
Methods

Cell Culture
Human saphenous vein ECs were isolated from outgrowths of explants from unused portions of saphenous veins harvested at coronary artery bypass surgery. Cells were cultured in medium 199 (BioWhittaker) containing 25 mmol/L HEPES, 1% heparin, 50 mg/L EC growth factor, 1% glutamine, 1% penicillin-streptomycin, and 5% FCS on lowpyrogen fibronectin (1.5 mg/cm 2 ). The cells used wereϾ99% von Willebrand factor-positive by flow cytometry analysis and exhibited in culture the typical "cobblestone" growth pattern seen in ECs. These experiments used ECs at passages 2 to 5. For treatment with PPAR␣ activators [docosahexaenoic acid (DHA); eicosapentaenoic acid (EPA); 5,8,11,14-eicosatetraenoic acid (ETYA); fenofibrate; and clofibrate; all from Sigma; and WY14643 from Biomol] or PPAR␥ activators [15d-PGJ 2 (Calbiochem); 9-hydroxy-(S)-10,12-octadecadienoic acid (9(S)-HODE) and 13(S)-HODE, both from Cayman Chemical], ECs were preincubated in low-serum medium (0.1% FCS) for 12 hours and then stimulated for the times indicated. Bovine ECs and human fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM, BioWhittaker) containing 1% glutamine, 1% penicillin-streptomycin, and 10% FCS.
NIH3T3-L1 preadipocytes, originally obtained from American Type Culture Collection (Manassas, Va) and generously provided to us by Dr Bruce Spiegelman, Dana Farber Cancer Institute, Boston, Mass, were cultured in DMEM, 10% bovine calf serum, and 1% penicillinstreptomycin. Differentiation of preadipocytes into adipocytes was induced as described by others. 17 Monocyte-derived macrophages were cultured as described before. 30 
RNA Extraction and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA from 10 7 cells was isolated by the single-step guanidinium thiocyanate-phenol-chloroform method with the use of RNAzol from Tel-Test. Two microgram of total RNA was reverse-transcribed into cDNA with 1 U/mL reverse transcriptase (Superscript, Gibco-BRL) at 37°C for 1 hour in standard buffer. Amplification of PPAR␥ cDNA used 2 oligonucleotide primers from nucleotides ϩ384 to ϩ705 (a 321-bp fragment): sense-primer, 5Ј-CGCGGGAATTCGGTGAAAC-TCTGGGGAGATTC-3Ј; antisense primer, 5Ј-CGCGGGATTCGT-TGACACAGAGATGCCATTC-3Ј. The primers were designed to detect all PPAR␥ isoforms. For the amplification of GAPDH cDNA, 2 oligonucleotide primers were used (a 452-bp fragment): sense-primer, 5Ј-ACCACAGTCCATGCCATCAC-3Ј; antisense primer, 5Ј-TCCAC-CACCCTGTTGCTGTA-3Ј. PCR was carried out in a standard buffer (Gibco-BRL) with 200 ng of each primer (IDT), 33 mmol/L MgCl 2 , and 0.5 U Taq polymerase (Gibco-BRL) for 30 cycles. PCR products (10 L/25 L) were analyzed on a 2% agarose gel.
Northern Blot Analysis
Five micrograms of total RNA from unstimulated or 15d-PGJ 2 -stimulated ECs was used for standard Northern blot analysis. After electro- 
Preparation of Nuclear and Cytosolic Extracts and Western Blot Analysis
For Western blotting, nuclear and cytosolic extracts of 10 7 cells were prepared. Cells were lysed in 10 mmol/L HEPES, pH 7.9, 1.5 mmol/L MgCl 2 , 10 mmol/l KCl, and 0.5% NP-40. Nuclei were pelleted at 13 000g for 5 minutes, and the resulting supernatant was used as the cytosolic fraction. Nuclei were lysed in 20 mmol/L HEPES, pH 7.9, 1.5 mmol/L MgCl 2 , 420 mmol/L NaCl, and 0.2 mmol/L EDTA. After centrifugation at 13 000g for 5 minutes, the supernatant was diluted in an equal volume of 20 mmol/L HEPES, pH 7.9, 100 mmol/L KCl, 0.2 mmol/L EDTA, and 20% glycerol and used as the nuclear extract. Protein concentration of nuclear and cytosolic extracts was determined colorimetrically (Pierce). Processed samples were applied to 10% SDS-polyacrylamide gel electrophoresis (PAGE) gels and transferred to nitrocellulose membranes (Millipore) by semi-dry blotting, as described previously. 31 Membranes were treated overnight with Tris-buffered saline-Tween containing 5% dry milk and incubated with goat anti-human PPAR␥ antibodies (mAbs; Santa Cruz, San Diego, Calif) for 1 hour. After being washed, the membranes were incubated with horseradish peroxidaseconjugated rabbit anti-goat mAbs. Antigen detection was performed with a chemiluminescence detection system (NEN). Nuclear extracts from PPAR␥-transfected human skin fibroblasts served as a positive control.
For the detection of secreted PAI-1 in supernatants from unstimulated or stimulated ECs, 50 L from 500 L total supernatant was subjected to 10% SDS-PAGE and processed as indicated above. For the detection of PAI-1, membranes were stained with a mouse anti-human PAI-1 mAb (American Diagnostica Inc, Greenwich, Conn). Quantification was performed using the NIH-Image densitometry software.
Immunohistochemistry of Human Carotid Artery Specimens
Surgical specimens of human carotid arteries were obtained by protocols approved by the Human Investigation Review Committee at the Brigham and Women's Hospital, Boston, Mass. Serial cryostat sections (5 mm) were cut, air dried onto microscopic slides, and fixed in acetone at Ϫ20°C for 5 minutes. Staining for PPAR␥ was performed with a polyclonal rabbit anti-human PPAR␥ peptide antibody (a generous gift from Dr Mitchell Lazar, University of Pennsylvania, Philadelphia) ECs were identified by staining with anti-CD31 antibody (Dako, Carpinteria, Calif). Sections were preincubated with PBS containing 0.3% hydrogen peroxidase activity and stained for 1 hour with primary antibody diluted in PBS supplemented with 5% appropriate serum. Negative control was performed by preabsorbing the anti-PPAR␥ antibodies with the peptide from which the antibody had been derived, subsequently using these "preabsorbed PPAR␥ antibodies" at similar concentrations as in experimental conditions. Finally, sections were incubated with the respective biotinylated secondary antibody (Vector Laboratories, Burlingame, Calif) followed by avidin-biotin-peroxidase complex (Vectastain ABC kit). Antibody binding was visualized with 3-amino-9-ethylcarbazole (Vector Laboratories) or with true blue peroxidase substrate (Kirkegaard & Perry Laboratories). Sections were counterstained with Gill's hematoxylin or contrast red (Kirkegaard & Perry Laboratories).
Transient Transfection Assay
Bovine ECs were transiently transfected with PPRE 3 -TK-luciferase (LUC) 17 (generously provided by Dr Bruce Spiegelman, DFCI) and pCMV-␤-galactosidase (␤-gal), by using lipofectamine, according to the manufacturer's protocol (Gibco-BRL). After incubation for 5 hours liposomes were removed, and after 12 hours of culture in DMEM with 10% FCS, cells were stimulated in DMEM containing 0.1% FCS with 15d-PGJ 2 at the indicated concentrations. Cells were harvested after 24 hours, and luciferase and ␤-gal activity was measured using the dual-light assay (Tropix).
With similar techniques, human skin fibroblasts were transfected with the PPAR␥ expression construct (pCMX-PPAR␥; generously provided by Dr Bruce Spiegelman, DFCI) at different concentrations (100 ng/5ϫ10 6 cells or 250 ng/5ϫ10 6 cells). To verify similar transfection efficiency under all conditions tested, we cotransfected cells with pCMV-␤-gal (500 ng/5ϫ10 6 cells). Cells were stimulated for 24 hours in serum-free medium with or without 5 mol/L 15d-PGJ 2 , harvested, and processed as described above.
Statistical Analysis
Results of the experimental studies are reported as meanϮSEM. Differences were analyzed by Student's paired t test. A value of PϽ0.05 in the 2-tailed test was regarded as significant.
Results
Human ECs Express PPAR␥ mRNA and Protein
Cultured human ECs express PPAR␥ mRNA as determined by RT-PCR ( Figure 1A ). Western blot analysis revealed PPAR␥ protein expression in the nuclear fraction but not in the cytosolic preparation ( Figure 1B, top) . The identity of the detected band was confirmed by its size and comigration with a signal from the nuclei of PPAR␥-transfected human fibroblasts. Nuclei from untransfected fibroblasts exhibited no similar signal of this size.
Comparison of PPAR␥ expression in ECs with other known PPAR␥-expressing cells (preadipocytes, adipocytes, and monocyte-derived macrophages) by both RT-PCR and Western blotting suggests that PPAR␥ is present at levels slightly less than in preadipocytes and monocyte-derived macrophages and substantially less than in differentiated adipocytes ( Figure 1A , top, and 1B, bottom). Northern blotting revealed barely detectable PPAR␥ in ECs (data not shown).
ECs in Human Carotid Arteries Express PPAR␥
Immunohistochemistry of human carotid arteries revealed PPAR␥ staining in the nuclei of ECs ( Figure 2B ). ECs were identified by immunoreactive CD31 (PECAM-1) in parallel sections (Figure 2A ) No immunostaining was observed when parallel sections were stained with anti-PPAR␥ antibodies preabsorbed with peptide ( Figure 2C ), indicating the specificity of the detected signals.
Treatment of PPRE-Luciferase-Transfected Bovine ECs With the PPAR␥ Activator 15d-PGJ 2 Increases Luciferase Activity
To assess the presence of functional endogenous PPAR␥ in ECs, we transiently transfected bovine ECs with a PPRE-luciferase construct and stimulated these cells with increasing amounts of the PPAR␥ activator 15d-PGJ 2 . Luciferase activity was assayed and normalized to the ␤-gal activity of a cotransfected pCMV-␤-gal construct. Stimulation with 15d-PGJ 2 increased normalized luciferase activity in a concentration-dependent manner, with a maximal 5.9Ϯ1.2-fold increase (PϽ0.05, nϭ3) at 10 mol/L 15d-PGJ 2 ( Figure 3 ). These results suggest the presence of inducible PPAR␥ activity in these cells.
PPAR␥, but Not PPAR␣, Activators Increase PAI-1 mRNA and Protein Expression in Human ECs
To investigate the effect of PPAR␥ activation on PAI-1 mRNA expression in human ECs, they were stimulated with the PPAR␥ activators 15d-PGJ 2 (10 mol/L), 9(S)-HODE (20g/L), or 13(S)-HODE (20g/L) for 18 hours, and Northern blot analysis was then performed. Unstimulated cells showed low PAI-1 mRNA expression, whereas stimulation with all tested PPAR␥ activators increased PAI-1 mRNA levels, with a maximum response seen with 15d-PGJ 2 ( Figure 4A ).
Western blotting of EC supernatants collected after 24 hours of treatment with the same PPAR␥ activators as above revealed an increase in PAI-1 protein ( Figure 4B ) in a pattern consistent with the Northern blot data. Using the most potent PPAR␥ activator, 15d-PGJ 2 , we found a concentration-dependent increase in PAI-1 secretion from human ECs, with a maximal 6.0Ϯ1.7-fold rise at 10 mol/L 15d-PGJ 2 compared with unstimulated cells (Pϭ0.03, nϭ3; Figure 4C ). In contrast, none of 6 different PPAR␣ activators increased PAI-1 protein levels in human ECs ( Figure 4D ).
Overexpression of PPAR␥ in Human Fibroblasts Increases PAI-1 Expression in Response to 15d-PGJ 2 in a Concentration-Dependent Manner
To investigate whether PPAR␥ can indeed increase PAI-1 levels, we turned to an artificial approach that would permit a demonstration of PPAR␥'s influence on PAI-1 expression. To do so, we overexpressed PPAR␥ in human fibroblasts and measured PAI-1 protein levels in supernatants of cells incubated with or without 15d-PGJ 2 . This strategy allowed studies to be done in readily transfectable cells that endogenously express PAI-1 but that have only low levels of PPAR␥. Untransfected fibroblasts, expressing PPAR␥ at negligible levels ( Figure 1B) , secrete PAI-1 under basal conditions at very low levels. Introduction of increasing amounts of the PPAR␥ expression construct enhanced PAI-1 secretion from these cells in proportion to the amount of transfected DNA. Consistent with our finding in ECs, treatment with 15d-PGJ 2 further augmented PAI-1 in the supernatants of these transfected fibroblasts compared with unstimulated cells (Figure 5A, top) . Densitometry of 15d-PGJ 2 
Discussion
We hypothesized that PPAR␥ might be expressed and active in regulating gene transcription in human ECs. If so, associations between triglyceride levels, obesity, and coagulation suggested that PAI-1 might be a PPAR␥ target gene. Our findings support both of these hypotheses.
Human ECs express PPAR␥ mRNA, as demonstrated by RT-PCR. Western blots showing a band co-migrating with PPAR␥-transfected fibroblasts established that human ECs express PPAR␥ protein. ECs contain slightly less but comparable amounts of PPAR␥ protein relative to preadipocytes and monocyte-derived macrophages. The lack of a strong PPAR␥ signal in Northern blot analysis agrees with other PPAR reports. 27, 32 The functional relevance of a given protein does not depend solely on mRNA levels but also on its in vivo translation and protein half-life. 33, 34 Importantly, ECs in vivo clearly contain PPAR␥ protein, as shown by immunohistochemistry of human carotid arteries. Furthermore, the ability to activate a canonical PPRE transfected into bovine ECs with 15d-PGJ 2 strongly supports the presence of a functional PPAR␥. We found that PPAR␥ activation in ECs, with either 15d-PGJ 2 or the HODEs, increased PAI-1 expression.
15d-PGJ 2 , a metabolite of PGD 2 , potently stimulates PPAR␥, exhibits much less activity toward PPAR␣ or PPAR␦, 19, 21, 35 and lacks a known role in other transcriptional signaling pathways. PPAR␣ activation is an unlikely mechanism for PAI-1 induction in ECs, given the lack of an effect of multiple PPAR␣ activators on PAI-1 protein levels. Furthermore, the stronger induction of PAI-1 by 15d-PGJ 2 reported here, compared with that elicited by the HODEs, agrees with previous studies suggesting that 15d-PGJ 2 is a more potent PPAR␥ ligand. 23 Finally, the proportionate induction of endogenous PAI-1 expression through increasing heterologous expression of PPAR␥ in fibroblasts bolsters the hypothesis that PAI-1 expression can be influenced by PPAR␥.
The PPAR family thus far is known to consist of 3 members, ␣, ␦, and ␥. Like all PPARs, PPAR␥ on activation forms heterodimeric complexes with the retinoic X receptor and associates with a PPRE site in the promoter of target genes. 25, 27, 36 PPAR␥, strongly implicated in adipogenesis, is induced early in adipocyte differentiation, after which it remains expressed at high levels. 37, 38 Little is known about PPAR␥ in nonadipocytes. Recent work suggests that PPAR␥ inhibits macrophage activation, thereby reducing cytokine production and macrophage gene expression. 28, 29 Similarly, we have localized PPAR␥ in macrophages in human atheromas and demonstrated a functional role for PPAR␥ in inhibiting matrix metalloproteinase-9 gelatinolytic activity elaborated by human monocyte-derived macrophages. 30 In contrast, recent reports, in addition to suggesting that components of oxidized LDL act as PPAR␥ ligands, also found that activation of PPAR␥ induced macrophage differentiation toward foam cells by increasing scavenger receptor expression. 22, 23 The net effect of PPAR␥ stimulation in atherogenesis thus remains unresolved 39 but could well be influenced by PPAR␥ in the endothelium.
PPAR␥ signaling in ECs is quite plausible. Adipose tissue is highly vascularized and, as such, rich in endothelium. ECs localize strategically at the interface between circulating lipid components and tissues. Some of these same lipid components, eg, 9-and 13-HODE, long known to activate ECs, have recently been found to act as PPAR␥ ligands. 23 Hence, ECs may well encounter at least 3 naturally occurring PPAR␥ ligands: 15d-PGJ 2 , 9(S)-HODE, and 13(S)-HODE.
PPAR␥ regulation of PAI-1 expression presents intriguing possibilities for insight into the known links between obesity and deep venous thrombosis, insulin resistance, non-insulindependent diabetes mellitus, myocardial infarction, and accelerated atherosclerosis. 2 PPAR␥ has been implicated in both mouse models and human forms of obesity. 24 Abundant laboratory and epidemiological evidence suggests the dysregulation of various metabolic and circulatory factors in obesity.
2 PAI-1 is one such example. PAI-1 levels correlate with serum triglycerides, increase with obesity, and fall with weight reduction, 2 findings that may reflect high adipocyte PAI-1 message levels. 40 In fact, adipose tissue, in addition to ECs and hepatocytes, may be an important source of PAI-1. 13 Elevated PAI-1 levels may explain in part findings such as those from the Nurses' Health Study, demonstrating obesity as an independent risk factor for pulmonary embolism. 41 Recent work reported a VLDL response element in the promotor region of the PAI-1 gene, located at residues Ϫ672 to Ϫ657. 42 Of note, this site has some characteristics of a PPAR binding site, although no data supporting an interaction with any PPAR were reported. It remains unclear where in the PAI-1 promotor PPAR␥ is acting. PPAR␥-dependent regulation of PAI-1 in ECs suggests the need for promoter studies in this cell type. It will also be of interest to investigate PPAR␥ regulation of PAI-1 in other cells such as adipocytes.
The present data implicate PPAR␥ as a novel regulator of gene expression in vascular cells, suggesting that PPAR␥ positively controls gene expression of PAI-1 in ECs, thus potentially promoting thrombosis. Of note, the PPAR ligands used here were naturally-occurring activators. It remains unclear if the synthetic thiazolidinediones such as troglitazone would have similar effects. In fact, clinical studies suggest that troglitazone decreases serum PAI-1 levels in some groups of patients with insulin resistance. 43 This PPAR␥ effect, like the induction of foam cells, might promote atherogenesis; in contrast, inhibition of macrophage activation and matrix metalloproteinase-9 activity through PPAR␥ might limit it. PPAR␥, as a highly regulated central transcriptional pathway present in various cell types, might well have varying effects on a complex pathological process like atherosclerosis. The data presented here suggest that PPAR␥, as a novel mediator in EC signaling, must be considered in attempting to understand atherogenic mechanisms.
